SEN. PRYOR's ATTENTION TO PHARMACEUTICALS MAY MODERATE
SEN. PRYOR's ATTENTION TO PHARMACEUTICALS MAY MODERATE with the impending departure of his key aide in that area, John Coster. A veteran of three Congressional sessions on the Senate Aging Committee, Coster has provided the staff leadership behind Sen. Pryor's (D-Ark.) active hearing schedule and his high-profile campaign against pharmaceutical price increases. Although Coster's departure has not been officially disclosed, the Senate staffer is expected to leave Capitol Hill within the next two months. Coster, who has previously worked for two pharmacy associations (APhA and ASHP), may be returning to a private sector position relating to policy issues affecting pharmacy.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth